Posts

New Genomic Test Shows Promise for Predicting Prostate Cancer Outcomes in Diverse U.S. Veterans

Image
Validation of the Prostatype® P-score for predicting prostate cancer specific mortality in a multiethnic U.S. veterans cohort | Prostate Cancer and Prostatic Diseases BLUF (Bottom Line Up Front) A new validation study published in Prostate Cancer and Prostatic Diseases demonstrates that the Prostatype P-score test—which can be performed locally rather than sent to reference laboratories—accurately predicted prostate cancer death in a predominantly African American cohort of U.S. veterans. The test achieved high accuracy (c-index of 0.87) and performed particularly well in intermediate-risk patients, the group that most needs better risk stratification tools. Unlike competing tests, this one can be run in-house at hospitals or certified facilities, potentially reducing wait times and costs while providing critical information to help match treatment intensity to disease aggressiveness. A Critical Gap in Cancer Care One of the most challenging aspects of prostate cancer diagnosis i...
Post a Comment
Read more

Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study

Image
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study | Prostate Cancer and Prostatic Diseases Real-World Evidence Confirms Enzalutamide's Strong Performance in Newly Diagnosed Metastatic Prostate Cancer IPCSG Newsletter Article January 2026 BLUF (Bottom Line Up Front) The largest international real-world study of enzalutamide (Xtandi) in metastatic hormone-sensitive prostate cancer confirms the drug's excellent survival outcomes and favorable safety profile outside of clinical trials. The ARON-3 study of 424 patients across 9 countries found that achieving ultra-low PSA levels (≤0.2 ng/mL) within months of starting treatment strongly predicts long-term survival. Even elderly patients over 70 and those with poorer performance status—groups typically excluded from clinical trials—experienced good outcomes with manageable side effects. These findings validate enzalutamide as a strong first-line trea...
Post a Comment
Read more

Rebuilding Trust: Why Patient-Doctor Communication Matters More Than Ever in Cancer Care

Image
Reengaging Patients in Medical Oncology With Scientific Discourse | CancerNetwork BLUF (Bottom Line Up Front): Trust in physicians and hospitals has plummeted from 71.5% to 40.1% between 2020-2024, driving cancer patients toward unvetted online sources. Key barriers include communication failures—oncologists using incomprehensible jargon, minimizing treatment side effects without providing quantified risks, and understating the realities of procedures and recovery. Patients report being told biopsies "will hurt" when they're actually excruciating, or learning about six-week catheters only after surgery. Medical oncologists are calling for honest procedural communication, transparent discussion of side effect probabilities with monitoring plans, plain-language dialogue, and patient-centered care to rebuild trust and improve outcomes. The Trust Crisis in Healthcare The numbers are sobering. According to a comprehensive 50-state survey published in JAMA Network Open in...
Post a Comment
Read more